Use of bone health agents (BHAs) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) after abiraterone (Abi): an interim review of REASSURE
Authors
Sternberg, CTombal, B
Miller, K
Saad, F
Sartor, O
Sade, J
Logothetis, C
Bellmunt, J
Dizdarevic, S
Harshman, L
Logue, John P
Baldari, S
Richardson, T
Bottomley, D
Schostak, M
Bayh, I
Kalinovsky, J
Higano, C
Affiliation
Medical Oncology, San Camillo Forlanini Hospital, Rome, ItalyIssue Date
2018
Metadata
Show full item recordCitation
Sternberg CN, Tombal B, Miller K, Saad F, Sartor O, Sade JP, et al. 826P Use of bone health agents (BHAs) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) after abiraterone (Abi): an interim review of REASSURE. Ann Oncol. 2018;29(suppl_8):288.Journal
Annals of OncologyDOI
10.1093/annonc/mdy284.035Additional Links
https://dx.doi.org/10.1093/annonc/mdy284.035Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdy284.035